Earnings were down 15 percent due to a 30 percent fall in sales of Taxus drug coated stents.
Boston Scientific announced that it had resolved quality deficiencies that the FDA had found in one of Guidant's plants used for manufacturing CRM devices, giving reassurance to shareholders that Boston is making steady progress in resolving its quality control issues, and sending shares up 7%.
Two clinical studies are released: Abbott Labs report that Abbott’s Xience V stent is more effective than Boston Scientific’s Taxus, and an independent study shows that stents are not more effective than non-invasive medical therapy.
Edit Metric
